MSH2 and thymus lymphoma: BM transplantation with different cell doses was also performed, and recipients of all cell doses from 1x106 to 1x105 developed T-lymphomas, and recipients of 1x105 MSH2-/- BM cells developed thymic lymphomas with slightly longer, but not significant, latency compared to the recipients of 1x106 (S1 Fig).